CD133, Selectively Targeting the Root of Cancer

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Cancer stem cells (CSCs) drive tumor initiation, self-renewal, and chemotherapy resistance.
• Drug-refractory relapse is a major challenge in cancer research, often linked to CSCs.
• CD133 is a promising CSC marker, though not universally expressed.

Purpose of the Study:

• To review novel biological agents targeting CD133 for CSC elimination.
• To discuss two distinct approaches utilizing anti-CD133 single chain variable fragments (scFv).

Main Methods:

• Development of anti-CD133 scFv for targeted delivery.
• Utilizing scFv to deliver catalytic toxins to CSCs.
• Employing scFv to deliver immune system components for CSC targeting.

Main Results:

• Two distinct biological agent strategies targeting CD133 were investigated.
• Both approaches demonstrated high efficacy in selectively targeting CD133.
• The agents showed potential for specific and efficient CSC elimination.

Conclusions:

• Targeting CD133 with biological agents offers a promising strategy against CSCs.
• scFv-based delivery systems are effective for both toxin and immune component payloads.
• These CD133-associated agents present a novel therapeutic avenue for refractory cancers.